Ellen MacCracken
Papers
2
Total Citations
46
H-Index
1
About
Dr. Ellen MacCracken is a leading oncologist and clinical researcher whose work is reshaping treatment paradigms for human papillomavirus-positive oropharyngeal cancer (HPV+ OPC). Her research centers on immunotherapy integration and response-adaptive de-escalation strategies—approaches that aim to reduce treatment toxicity without compromising survival. In her landmark 2024 study, Dr. MacCracken demonstrated that neoadjuvant nivolumab combined with chemotherapy, followed by response-adaptive therapy, can effectively treat HPV+ OPC, challenging the traditional role of immune checkpoint inhibitors in curative settings. This work has quickly garnered 45 citations, reflecting its immediate impact on clinical practice. She further advanced the field with her 2025 pooled analysis, which confirmed that de-escalated, response-adapted treatment preserves both functional outcomes and survival in this favorable-prognosis population. By systematically showing that less aggressive therapy can maintain quality of life while achieving excellent oncologic control, Dr. MacCracken is helping to set a new standard of care. Her contributions are pivotal for students and researchers interested in precision oncology, immunotherapy, and the ongoing effort to minimize long-term side effects for cancer survivors.
Research Focus
Key Achievements
Top Papers
- 1
- 2